Sanofi snags Canadian nod for Lemtrada; Novartis cutting 300 jobs;

@FierceBiotech: Genzyme's Lemtrada has been approved in Canada for treatment of multiple sclerosis. Release | Follow @FierceBiotech

@JohnCFierce: Trending: Why did Roche kill off its Alzheimer's program for the BACE inhibitor RG7129? Editor's corner | Follow @JohnCFierce

@DamianFierce: AVEO says tivozanib's colorectal cancer data isn't looking good, taking another ~15% off its already ailing shares. Story | Follow @DamianFierce

@EmilyMFierce: Report: Life science research needs standards to curb irreproducible studies. Story from FierceBiotech Research | Follow @EmilyMFierce

> Sanofi ($SNY) and Genzyme picked up Canadian approval for their multiple sclerosis drug Lemtrada, a long-in-development treatment that has faced FDA skepticism. More

> Novartis ($NVS) is planning to shed 300 jobs and shut down a Canadian eye care plant. Story

> Roche ($RHHBY) is going in-house for companion diagnostics, tasking its Ventana segment with developing tests for its cancer compounds. Article

Medical Device News

@FierceMedDev: Chutes & Ladders this week: Merck's Kim resigns to teach at Stanford med school. Feature | Follow @FierceMedDev

@MarkHFierce:  Quest Diagnostics improved the lower-end of its 2013 earnings expectations, but still says overall revenue will dip. Story | Follow @MarkHFierce

@MichaelGFierce: Brain implant recovers motor function by boosting neuron communication. Item | Follow @MichaelGFierce

@GalenMoore: Researchers say they've synthesized erythropoietin, a hormone used for doping. More via Nature | Follow @GalenMoore

> Roche pairs Ventana breast cancer test with two more of its blockbuster drugs. News

> Brain implant recovers motor function by boosting neuron communication. Article

> Quest boosts its 2013 earnings guidance, but warns Dx market troubles remain. More

> Silver service: S&N's Durafiber Ag now dresses European wounds, too. Piece

Pharma News

@FiercePharma: Trending now: Think Fast: New cognition study could add $350M to Lundbeck's Brintellix sales. Yesterday's story | Follow @FiercePharma

@EricPFierce: Merck KGaA sees upside in allergy meds, emerging markets. New plant to make allergy meds 4 emerging markets. Story from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: Good news for Vivus: Sanofi has signed on to sell ED drug Stendra in emerging markets. Release | Follow @CarlyHFierce

> Torrent buys Elder's domestic business, keeping it Indian controlled. Report

> 300 Novartis workers to be sacked when Alcon plant closes next year. News

> Sanofi signs on to sell Vivus ED drug in emerging markets. Story

> Emergent BioSolutions expanding with $222M deal to buy Cangene. More

Suggested Articles

Karen DeSalvo's appointment is the latest in a string of hires that deepen the tech giant’s investment in and focus on healthcare.

Spring Bank’s hepatitis B drug, given in tandem with Gilead’s Vemlidy, tamped down on chronic disease in 23% of patients in a phase 2 study.

Gilead names Dickinson to CFO role; MedImmune CSO Herbst nabs CSO job at Pyxis; Checkmate picks up Wooldridge for CMO.